You are on the Investment solutions website for advisors & wealth management firms.
Browse more Fidelity websites here.
Portfolio Manager Insights
Small-cap biotechs showing new signs of strength
Innovative therapies, an improving environment for potential merger activity and low stock valuations are a prescription for success among small-cap biotech stocks, says Fidelity's Eirene Kontopoulos.
- The stocks of small-cap biotech firms are newly invigorated following a period of tight lending conditions and other factors that crimped their ability to raise capital to conduct the research needed to advance innovative treatments, according to Fidelity Portfolio Manager Eirene Kontopoulos.
- "Promising new product discoveries and therapies, along with low valuations and richer prospects for mergers and acquisitions, provide a compelling opportunity to invest in small-cap biotechs," says Kontopoulos, who manages Fidelity Advisor® Biotechnology Fund.
- In helming the industry-based, equity-focused strategy since 2018, Kontopoulos, who holds a doctorate in neuroscience from Harvard Medical School, believes that successfully investing in biotechnology requires a competitive edge on the science behind the drugs, the likelihood of clinical success and the size of the total addressable market. She favors companies that can help develop what she considers to be the most innovative therapies.
- Historically, small biotechnology firms have been in the vanguard of new product discoveries and treatments, including innovation in oncology therapies, gene editing and vaccines, Kontopoulos says. But in recent years, small-caps in the industry have lagged the performance of their larger-cap counterparts, partly due to higher interest rates and tight lending conditions, which she says, "crimped the ability of many small firms to raise capital to conduct the research needed to advance innovative medicines."
- Now, a reversal is taking hold, with Kontopoulos and Fidelity's biotech team believing the opportunity for smaller-cap biotechs is ripe, given their low valuations relative to large-cap biotech companies. "In 2024, aggregate clinical trial results among small-cap biotechs added considerable market value, although it wasn't fully reflected in stock prices, by our calculation," she explains.
- At the same time, she notes, earnings margins among the biotech components in the S&P SmallCap 600® Index are expected to potentially return to positive territory in 2025, after a difficult 2024.
- Additionally, she thinks merger-and-acquisition activity could rebound. Large-cap biotechs and major pharmaceutical companies have accumulated near-record cash of late, and many need to replace drugs set to lose patent protection, she says.
- "More deals could be coming if lower interest rates spur risk-taking," according to Kontopoulos. "They could center on smaller-cap firms, as these types of targeted acquisitions are easier to integrate and often face less regulatory scrutiny than large acquisitions."
- Crinetics Pharmaceuticals is a high-quality, small-cap fund holding in the small-cap category that Kontopoulos has particularly liked, describing its focus on small-molecule endocrinology. She believes it may get approval from the Food and Drug Administration in 2025 for an oral treatment for acromegaly, likely recording about $700 million in peak sales, by Fidelity's estimate.
- Another top idea is Xenon Pharmaceuticals, for which the biotech team expects favorable phase 3 epilepsy data later this year. "We estimate roughly $1 billion in peak sales here," she says, adding that the drug also is being studied as a potential treatment for depression.
- Crinetics and Xenon were among the fund's largest overweight positions versus the industry benchmark as of April 30.
Featured Fund
Fidelity Advisor Biotechnology Fund (FBTIX)
Seeks to provide capital appreciation.
Related insights
View all
Portfolio Manager Insights
How Roku is remaking the market for advertising on streaming services
Following the introduction of Roku Ads Manager, the streaming platform gets top billing in helping advertisers reach consumers while they watch their favorite television shows, says Fidelity's Becky Baker.
Portfolio Manager Insights
Looking to the cosmos for opportunity
Space exploration is no longer the stuff of science fiction; it's a rapidly evolving industry that's reshaping the way we think about technology, defense and connectivity, says Fidelity's Chris Lin.
Portfolio Manager Insights
Specialty drugmakers poised for a game-changing outcome
Fidelity's Eddie Yoon says specialty drug manufacturers in the biotech industry with promising clinical data have the potential for blockbuster growth.
For specific fund information such as standard performance and holdings, please go to the "Funds Managed" link on this page.
Investment decisions should be based on an individual’s own goals, time horizon, and tolerance for risk. Nothing in this content should be considered to be legal or tax advice, and you are encouraged to consult your own lawyer, accountant, or other advisor before making any financial decision. These materials are provided for informational purposes only and should not be used or construed as a recommendation of any security, sector, or investment strategy.
Fidelity does not provide legal or tax advice and the information provided herein is general in nature and should not be considered legal or tax advice. Consult with an attorney or a tax professional regarding your specific legal or tax situation.
Past performance and dividend rates are historical and do not guarantee future results.
Investing involves risk, including risk of loss.
Diversification does not ensure a profit or guarantee against loss.
Sector funds can be more volatile because of their narrow concentration in a specific industry. Growth stocks can perform differently from other types of stocks and the market as a whole and can be more volatile than other types of stocks. Value stocks can perform differently than other types of stocks and can continue to be undervalued by the market for long periods of time. • Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. • Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks, all of which are magnified in emerging markets. • In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation, credit, and default risks for both issuers and counterparties. • Lower-quality bonds can be more volatile and have greater risk of default than higher-quality bonds. • The municipal market is volatile and can be significantly affected by adverse tax, legislative, or political changes, and the financial condition of the issuers of municipal securities. • The securities of smaller, less well-known companies can be more volatile than those of larger companies. • The funds can invest in securities that may have a leveraging effect (such as derivatives and forward-settling securities) that may increase market exposure, magnify investment risks, and cause losses to be realized more quickly. • Leverage can magnify the impact of adverse issuer, political, regulatory, market, or economic developments on a company. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Although the companies that the fund invests in may be highly leveraged, the fund itself does not use leverage as an investment strategy. Changes in real estate values or economic downturns can have a significant negative effect on issuers in the real estate industry. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Third-party marks are the property of their respective owners; all other marks are the property of FMR LLC.
935099.89
D930C4669EBC4736942C2C3CD15C9483